ONCOLOGY

Nationwide data from Sweden show changes in treatment of mantle cell lymphomas.

Will anti-CD19 activity improve responses rates in DLBCL? The answer is sought in a cross-trial comparison.

Is it possible for fit patients with chronic lymphocytic leukemia and a good prognosis to skip immunochemotherapy in favor of ibrutinib?

Randomized global FORUM trial was stopped because of futility.

After adjusting for age, positive trends become apparent in the survival of elderly Danish AML patients between the years 2000 and 2016.

A more efficient regimen may be in sight for “typical” patients with newly diagnosed chronic lymphocytic leukemia.

Independent research from Freiburg University (Germany) shows significant benefits of add-on all-trans retinoic acid for frail patients with AML.

Four cycles of chemotherapy sufficient in patients responding to treatment.

A phase 1 study with heavily pretreated patients with relapsed or refractory ALL reports promising response rates for the combination of 2 BCL-2-inhibitors.

Findings from a multicenter risk-adapted study.

Physicians are again discussing hospice care with patients.

UK TARGET CML study finds little evidence that cardiovascular risk factors are considered during TKI management.

PFS benefit was seen across all subgroups.

While positive overall, the findings will need to be confirmed in larger multinational and registry studies.